Guardant Health's Liquid Biopsy Test Validates Melanoma Recurrence Prediction

  • Guardant Health's COSMOS-MEL01 study published in Cancer Research Communications validates Guardant Reveal™ liquid biopsy test for predicting melanoma recurrence.
  • Study analyzed 280 longitudinal surveillance samples from 48 patients with stage II–III melanoma, detecting 81% of distant recurrences with 100% specificity.
  • ctDNA detection preceded clinical identification of recurrence by a median of 70.5 days.
  • Guardant Reveal demonstrated up to 273-day lead time from ctDNA detection to recurrence.

Guardant Health's study provides strong evidence for the utility of liquid biopsy in predicting melanoma recurrence, addressing a critical gap in current postoperative care. The findings could drive broader adoption of molecular residual disease (MRD) detection in oncology, potentially reshaping surveillance and treatment strategies for high-risk melanoma patients. The rising incidence of melanoma further underscores the market need for such predictive tools.

Clinical Integration
How quickly Guardant Reveal will be adopted into standard postoperative treatment and surveillance protocols for melanoma.
Market Expansion
Whether Guardant Health can leverage these results to expand the use of Guardant Reveal into other cancer types beyond melanoma.
Competitive Dynamics
The pace at which competitors develop similar liquid biopsy technologies for MRD detection and recurrence monitoring.